Rising HIV Infections Driving Growth In HIV Clinical Trials Market Due To Increasing Disease Burden And Need For Effective Treatments: Strategic Insights Driving Human Immunodeficiency Viruses (HIV) Clinical Trials Market Momentum in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size By 2025?
In recent times, there has been significant growth experienced by the market of clinical trials for human immunodeficiency viruses (HIV). This market, which was valued at $1.77 billion in 2024, is projected to increase to $1.94 billion in 2025, marking a compound annual growth rate (CAGR) of 9.3%. The historic growth can be linked to factors including the rising incidence of drug-resistant strains of human immunodeficiency viruses, the growing call for personalized medicine in HIV care, emphasis on early detection and treatment, an increased count of clinical research organizations, and heightened awareness about HIV-related comorbidities.

How Big Is the Human Immunodeficiency Viruses (HIV) Clinical Trials Market Size Expected to Grow by 2029?
The market size for clinical trials focused on human immunodeficiency viruses (HIV) is projected to experience significant expansion in the upcoming years. By 2029, it's expected to reach a valuation of $2.73 billion, with a compound annual growth rate (CAGR) of 9.0%. The predicted growth within this period can be linked to factors such as a higher incidence of HIV infections, heightened awareness about HIV prevention and treatment strategies, a surge in the adoption of antiretroviral therapy, increased government funding for HIV research, and enhanced investment in biotechnology and pharmaceutical sectors. The forecast period will also witness notable trends like technological innovations in HIV diagnostic procedures, progress in antiretroviral therapy (ART) formulas, advancements in identifying biomarkers, the use of technology in remote patient monitoring solutions, and the amalgamation of digital health platforms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-viruses-hiv-clinical-trials-global-market-report

Which Key Market Drivers Powering Human Immunodeficiency Viruses (HIV) Clinical Trials Market Expansion and Growth?
The surge in human immunodeficiency virus (HIV) infections is anticipated to drive the expansion of the HIV clinical trials market. HIV infections denote the situation where the HIV virus attacks and weakens the immune system, heightening the vulnerability to infections and potentially leading to AIDS. The infection rise can largely be attributed to the lack of awareness about its transmission, leading to risky behaviour and delayed testing that enables the spreading of the virus. HIV clinical trials provide a ray of hope for HIV patients by testing new medications, vaccines, and treatment methodologies to refine prevention, better manage the virus, and eventually slow down disease progression and transmission. For example, as per the Minority HIV/AIDS Fund (MHAF), a government agency based in the US, there were around 39.9 million individuals globally living with HIV in 2023, which included 38.6 million adults and 1.4 million children, a significant increase from previous years. Therefore, the escalating incidence of HIV infections is fueling the expansion of the HIV clinical trials market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28244&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
Leading firms in the market for clinical trials for the human immunodeficiency virus (HIV) are concentrating on creating cutting-edge solutions such as injections for HIV prevention to boost the effectiveness of treatments and lower transmission rates. A preventative HIV injection is a long-acting injectable form of medication given on a scheduled basis to prevent infection with HIV in those at high risk by inhibiting the virus from causing infection in the body. For example, in August 2025, Gilead Sciences Inc., a pharmaceutical company based in the US, was granted approval by the European Union for a drug called Yeytuo (lenacapavir) to treat HIV. This drug is administered twice a year as an HIV preventative measure, has been shown in clinical trials to be nearly 100% effective and substantially decreases the chance of sexually contracted HIV-1. Its long-lasting dosage cycle makes it more convenient and easier to adhere to than the daily oral PrEP, addressing a significant shortfall in HIV prevention. It is intended for adolescents and adults who are at increased risk, with a goal of broadening access and contributing to a reduction in new HIV infection rates globally as part of extensive prevention strategies.

What Are the Emerging Segments in the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
The human immunodeficiency viruses (HIV) clinical trials market covered in this report is segmented as

1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical
2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations
5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users

Subsegments:
1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies
2) By Phase Ii: Dose-Finding Studies, Efficacy Studies
3) By Phase Iii: Pivotal Trials, Comparative Efficacy Studies
4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies
5) By Preclinical: In Vitro Studies, Animal Studies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28244&type=smp

Who Are the Global Leaders in the Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio.

Which are the Top Profitable Regional Markets for the Human Immunodeficiency Viruses (HIV) Clinical Trials Industry?
North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus (HIV) clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28244

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.